Apoptosis therapy in cancer: The first single-molecule co-activating p53 and the translocator protein in Glioblastoma

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Daniele, Simona ^a   Taliani, Sabrina ^a   Da Pozzo, Eleonora ^a   Giacomelli, Chiara ^a   Costa, Barbara ^a   Trincavelli, Maria Letizia ^a   Rossi, Leonardo ^a   La Pietra, Valeria ^b   Barresi, Elisabetta ^a   Carotenuto, Alfonso ^b   Limatola, Antonio ^b   Lamberti, Anna ^c   Marinelli, Luciana ^b   Novellino, Ettore ^b   Da Settimo, Federico ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN BINDING; PROTEIN MDM2; PROTEIN P53; TSPO PROTEIN, HUMAN;

AGONISTS; ANIMAL; APOPTOSIS; BINDING SITE; CELL CYCLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; GLIOBLASTOMA; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NUCLEAR MAGNETIC RESONANCE; PROTEIN ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; GLIOBLASTOMA; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, GABA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899080685     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04749     Document Type: Article

References (41)

1. Morphy, R. & Rankovic, Z. Designing multiple ligands-medicinal chemistry strategies and challenges. Curr. Pharm. Des. 15, 587-600 (2009).
2. O'Boyle, N. M. & Meegan, M. J. Designed multiple ligands for cancer therapy. Curr. Med. Chem. 18, 4722-4737 (2001).
3. Petrelli, A. & Giordano, S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 15, 422-342 (2008).
4. Mas-Moruno, C., Rechenmacher, F. & Kessler, H. Cilengitide: the first antiangiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10, 753-768 (2010).
5. Behm, T. et al. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. Clin. Neurol. Neurosurg. 115, 2142-2146 (2013).
6. Chowdhary, S. & Chamberlain, M. Bevacizumab for the treatment of glioblastoma. Expert. Rev. Neurother. 13, 937-949 (2013).
7. Green, D. R. & Walczak, H. Apoptosis therapy: driving cancers down the road to ruin. Nat. Med. 19, 131-133 (2013).
8. Griguer, C. E. & Oliva, C. R. Bioenergetics pathways and therapeutic resistance in gliomas: emerging role of mitochondria. Curr. Pharm. Des. 17, 2421-2427 (2011).
9. Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457-468 (2005). (Pubitemid 40719129)
10. Fulda, S., Galluzzi, L. & Kroemer, G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-64 (2010).
11. Castellano, S. et al. Synthesis and biological evaluation of 4-phenylquinazoline-2-carboxamides designed as a novel class of potent ligands of the translocator protein. J. Med. Chem. 55, 4506-4510 (2012).
12. Cosimelli, B. et al. Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein. Eur. J. Med. Chem. 46, 4506-4520 (2011).
13. Itahana, Y. & Itahana, K. Emerging roles of mitochondrial p53 and ARF. Curr. Drug Targets 13, 1633-1640 (2012).
14. England, B., Huang, T. & Karsy, M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 34, 2063-2074 (2013).
15. Villalonga-Planells, R. et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 6, e18588 (2011).
16. Costa, B. et al. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One 8, e72281 (2013).
17. Primofiore, G. et al. N, N-Dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J. Med. Chem. 47, 1852-1855 (2004). (Pubitemid 38380930)
18. Da Settimo, F. et al. Anxiolytic-like effects of N, N-dialkyl-2- phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J. Med. Chem. 51, 5798-5806 (2008).
19. Taliani, S. et al. Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization. J. Med. Chem. 53, 4085-4093 (2010).
20. Welsch, M. E., Snyder, S. A. & Stockwell, B. R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol. 14, 347-361 (2010).
21. Dalpiaz, A. et al. A concerted study using bindingmeasurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines toward mitochondrial benzodiazepine receptors. J. Med. Chem. 38, 4730-4738 (1995).
22. Shangary, S. & Wang, S. Small-molecule inhibitors of the MDM2-p53 proteinprotein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241 (2009).
23. Michelsen, K. et al. Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J. Am. Chem. Soc. 134, 17059-17067 (2012).
24. Gonzalez-Lopez de Turiso, F. et al. Rational design and binding mode duality of MDM2-p53 inhibitors. J. Med. Chem. 56, 4053-4070 (2013).
25. Papadopoulos, V. et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27, 402-409 (2006). (Pubitemid 44069585)
26. D'Silva, L. et al. Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J. Am. Chem. Soc. 127, 13220-13226 (2005). (Pubitemid 41377613)
27. Krajewski, M. et al. An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments. J. Med. Chem. 50, 4382-4387 (2007). (Pubitemid 47378836)
28. Dawson, R. et al. The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332, 1131-1141 (2003). (Pubitemid 37108805)
29. Persico, M. et al. New anticancer agents mimicking protein recognition motifs. J. Med. Chem. 56, 6666-6680 (2013).
30. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004). (Pubitemid 38174664)
31. Costa, B. et al. An antibody-free strategy for screening putative HDM2 inhibitors using crude bacterial lysates expressing GST-HDM2 recombinant protein. Drug. Test. Anal. 5, 596-601 (2013).
32. Kondo, S., Barnett, G. H., Hara, H., Morimura, T. & Takeuchi, J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10, 2001-2006 (1995).
33. Chelli, B. et al. PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells. J. Cell. Biochem. 105, 712-723 (2008).
34. Sami, A. & Karsy, M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol. 34, 1991-2002 (2013).
35. Prasad, G. et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-Oncology 13, 384-392 (2011).
36. Huey, R., Morris, G. M., Olson, A. J. & Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28, 1145-1152 (2007). (Pubitemid 46506716)
37. Morris, G. M. et al. Autodock4 and Auto Dock Tools4: automated docking with selective receptor flexiblity. J. Computational Chemistry 16, 2785-91(2009).
38. Pettersen, E. F. et al. UCSF chimera e a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
39. Reers, M. et al. Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 260, 406-417 (1995).
40. Hwang, T. L. & Shaka, A. J. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J. Magn. Reson. 112, 275-279 (1995).
41. Fadok, V. A. et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207-2216 (1992).